News & Insights
Federal Cannabis Rescheduling Decision Expected by the End of the Year
The secretary of the U.S. Department of Health and Services has suggested we may know by the end of this year whether cannabis will be rescheduled or descheduled from the Controlled Substances Act, which may be the key to a new revived “green rush” of capital into the financially-challenged cannabis industry.
New York Updates Proposed Adult Use Dispensary Regulations
Feldman Legal Advisors is pleased to share the recent changes to the New York State proposed adult use cannabis revised regulations, which were released by the Cannabis Control Board (CCB) and Office of Cannabis Management (OCM) last week.
5 Tips to a Successful “Distressed” Cannabis/Psychedelics Acquisition
Whether players in the cannabis and psychedelics industries like it or not, the era of acquisitions of troubled or struggling companies is here. Access to capital, the mother’s milk of these industries, has been severely restricted for over a year. As losses continue, debt matures and defaults grow, businesses seek strategic alternatives including M&A.
Australia Authorizes Therapeutic Access to MDMA and Psilocybin
On February 3, 2023, Australia’s Therapeutic Goods Administration (ATGA), a medical authority under the Department of Health and Aged Care, announced a change to the country’s regulatory classification of psilocybin and methylenedioxymethamphetamine (MDMA), allowing the compounds to be prescribed by psychiatrists for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), respectively. The decision was made after the government determined that there was sufficient medical and scientific evidence to support the conclusion that the substances will be beneficial for these conditions. This dramatic change makes Australia the first major country to legalize the therapeutic use of these substances.
What Does the New DEA Letter on THCO Mean for Novel Cannabinoids?
On February 13, 2023, the U.S. Drug Enforcement Administration (DEA) issued a regulatory opinion on the control status of tetrahydrocannabinol acetate ester (THCO), confirming that the agency classifies delta-8-THCO and delta-9-THCO as schedule 1 controlled substances.
